About_Suzhou Womei Biology Co.,Ltd

Company Profile

Suzhou Womei Biology Co., Ltd. (referred to as "Womei Biology") is a solution service provider in the bio-manufacturing industry. Its product portfolio includes customized media, bioreactors, immune adjuvants, and biochemical reagents, serving as a supplier for both upstream and downstream bioprocesses. The company also provides formulation production, process optimization, process validation, technical support, and supporting services for the bio-manufacturing sector.

Womei Biology operates R&D centers in Shanghai, Suzhou, and Wuhan, and has established production bases in Zhangjiagang and Shanghai. The company continuously enhances its process development capabilities, quality systems, management expertise, and production capacity. Building on its existing R&D and production infrastructure, Womei Biology is progressively expanding its business in technologies, products, and services related to bio-manufacturing processes, striving to deliver high-tech product and service support to the domestic biopharmaceutical industry.

Looking ahead, the company aims to provide process development and production support to enterprises in fields such as antibodies, vaccines, and cell therapy, thereby contributing to the advancement of the domestic biopharmaceutical industry.

Milestone

Development Path

2010

1.To establish Shanghai MIDI Biotechnology Co. , Ltd；

2.To develop the serum-free culture medium for insect cells in China;

3.To sign a cooperation agreement with the National Center for Biochemical Engineering and technology (Shanghai) to jointly carry out technical services;

2012

1.Suzhou Womei Biology Co. , Ltd. was established;

2.Signed and completed technical service projects with biological products enterprises;

3.The domestic market share of insect cell culture media products increased significantly;

2014

1. BHK serum-free medium has been proven through large-scale application.;

2.Animal vaccines of several genetic engineering subunits were completed and many clinical cases were declared;

2016

1.The establishment of the Bioreactor Product Division；

2.The official establishment of the Shanghai Songjiang R & D Center (genetic engineering and cell engineering) ；

3.The establishment of Suzhou Sinobiology, focusing on the new veterinary drug CRO business;

2018

1.Strategic cooperation agreements have been signed with enterprises in the industry, such as Jinyubiao, Ripp Biological, Qilu animal protection, etc. ;

2.East China University of technology to establish the animal vaccine adjuvant products division;

2020

1.Womei biology was established and settled in Fenghuang Town, Zhangjiagang, integrating the original media, reactor, adjuvant and other business;

2.Expansion of Shanghai R & D Center, it will form three laboratories of genetic engineering and diagnosis, cell engineering and microbial purification, with a total area of 2000 square meters；

3.More than 100 utility model patents for authorized invention of genetic engineering animal vaccine;

The sales revenue of the enterprise exceeds 100 million yuan

2022

1.Construction of a new production base in Zhangjiagang；

2.Strengthen its capabilities in vaccine CRO services；

3.Construction of a research and development centre in Shanghai；

4.Establishment of a holding company, Nantong WorldTex, facheng haoxin investment, focusing on high-end Bioreactor；

5.The establishment of the East China University of Science and Technology Bioreactor Process Control and intelligent manufacturing technology transfer centre;

2023

1.Leaders of the standing committee of the CPC Zhangjiagang Municipal Committee visited the WOMEI biology;

2.The IPO of the science and Technology Innovation Board was launched and signed;

3.The agreement was signed to enter the flying bio-pharmaceutical industry park in Zhangjiagang;

2024

(1) Shanghai R&D Center & Global Business Headquarters Completed;

(2) Synthetic Biology CDMO Factory Project Signed;

(3) Overseas Business Division Thriving;

(4) Synthetic Biology Industrial Division Growing Rapidly;

2025

(1) The Zhangjiagang Phase II Quality Control Center Completed;

(2) WorldTex (Shanghai)-Jinshan Factory Completed;

(3) Unveiling of the “Womei Lecture Hall" at the School of Biotechnology, East China University of Science and Technology;

(4) Approved as a Five-Star "Biomanufacturing Pilot Capability Construction Platform" by the Ministry of Industry and Information Technology;

(5) Approved as a "High-Performance Bioreactor" Initiative Undertaker by the Ministry of Industry and Information Technology, Undertaking 6 National-Level Key Projects;